Medlab Clinical Ltd is a renowned company that upholds its core values and corporate philosophy with utmost dedication. The company firmly believes in promoting innovative and evidence-based medical research to improve patient outcomes. With a focus on scientifically driven products, Medlab Clinical Ltd strives to develop and deliver advanced therapeutic solutions in the field of medical science. The company values integrity, commitment, and excellence, as it strives to provide cutting-edge diagnostics and personalized medicine. Medlab Clinical Ltd's dedication to upholding these values has made it a trusted name in the healthcare industry, offering high-quality solutions for better patient care.

Medlab Clinical Ltd is primarily present in Australia and New Zealand.

Some significant milestones achieved by Medlab Clinical Ltd include the successful completion of a Phase 2 trial for their lead drug candidate, NRGBiotic, for managing depression symptoms. The company has also received various regulatory approvals and successfully launched several products, including Nanabis, a cannabis-based product for pain management. Medlab Clinical Ltd has established collaborations with prestigious research institutions and universities worldwide, contributing to advancements in medical research. The company continues to expand its global reach, with strategic partnerships and acquisitions, positioning itself as an innovative leader in the field of personalized medicine and nutraceuticals.

Medlab Clinical Ltd is an Australian biotechnology company specializing in developing and commercializing novel therapeutic products for chronic diseases. Established in 2012, Medlab Clinical has rapidly emerged as a leader in the medical research and development sector. With a strong focus on scientific innovation, the company aims to improve patient outcomes through its advanced drug delivery systems and targeted treatments. Medlab Clinical has garnered recognition for its cutting-edge medical advancements, including patented NanoCelle™ technology. With a commitment to research excellence and a dedicated team of experts, Medlab Clinical continues to revolutionize the field of biotechnology and pave the way for groundbreaking medical solutions.

The main competitors of Medlab Clinical Ltd in the market include companies such as Sonic Healthcare Limited, Healius Limited, Integral Diagnostics Limited, and Capitol Health Limited. These companies also operate in the medical diagnostics and healthcare industry, offering similar services and solutions. Despite facing competition, Medlab Clinical Ltd has established a strong presence and reputation through its innovative offerings, research collaborations, and dedication to improving patient outcomes.

Medlab Clinical Ltd is primarily active in the healthcare and biotechnology industries.

The business model of Medlab Clinical Ltd is focused on innovative medical research and the development of therapeutic formulations. As a leading Australian biotech company, Medlab Clinical specializes in developing and commercializing nutraceuticals, pharmaceuticals, and diagnostic tools to improve patient outcomes. Medlab Clinical aims to leverage its expertise in advanced delivery platforms and nutraceutical products to address various health conditions, including pain management, depression, and chronic diseases. By prioritizing research-backed solutions and strategic collaborations, Medlab Clinical aims to transform healthcare through evidence-based treatments and personalized medicine.

Medlab Clinical KGV ir -0,69.

Medlab Clinical KUV ir 3,44.

AlleAktien kvalitātes vērtējums Medlab Clinical ir 2/10.

gaidāmā Medlab Clinical apgrozījums ir 4,38 milj. AUD.

gaidāmā Medlab Clinical peļņa ir -21,74 milj. AUD.

Medlab Clinical Ltd is an Australian company specializing in the development and provision of clinical diagnostic solutions for medical professionals. The company operates in three main divisions: diagnostic services, biotechnology, and research and development. The diagnostic services provide a variety of laboratory tests for medical conditions, including hormone tests, immune tests, and microbiology tests. The biotechnology division focuses on developing groundbreaking drugs and therapies for serious diseases such as inflammation and cancer. The research and development division invests in innovative technologies and products to meet the needs of medical professionals and their patients. Medlab Clinical offers a wide range of products and services, including probiotics for digestive and gut health, skin-friendly nutraceuticals, and blood tests for various medical conditions. The company's strong business model is based on innovation, research, and customer service. It aims to maintain its reputation as a leading provider of clinical diagnostic solutions and biotechnological developments through continuous innovation and excellent customer satisfaction.

Medlab Clinical izmaksā dividendes 0 AUD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Medlab Clinical vai uzņēmums nedod dividendes.

Medlab Clinical ISIN ir AU000000MDC8.

Medlab Clinical WKN ir A14R7W.

Medlab Clinical simbols ir MDC.AX.

Pēdējo 12 mēnešu laikā Medlab Clinical maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Medlab Clinical plāno maksāt dividendes 0 AUD apmērā.

Medlab Clinical pašreizējā dividendu rentabilitāte ir .

Medlab Clinical maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Medlab Clinical pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 AUD. Tas atbilst dividendes ražībai 0 %.

Medlab Clinical tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Medlab Clinical apmērā 0 AUD, kas tika izmaksāta 9.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 9.09.2024..

Pēdējās dividendes izmaksa notika 9.09.2024..

Gadā 2023, Medlab Clinical izmaksāja 0 AUD dividendes.

Medlab Clinical dividendes tiek izmaksātas AUD.